Navigation Links
Renaissance Surgical Arts at Newport Harbor Announces Single-Dose Radiation Treatment Alternative for Women with Early Breast Cancer
Date:2/10/2011

COSTA MESA, Calif., Feb. 10, 2011 /PRNewswire/ -- Renaissance Surgical Arts at Newport Harbor announced today that it is the first outpatient surgery center in the Western United States to offer intraoperative radiotherapy (IORT) using the INTRABEAM® System – the only device used in the TARGIT-A multicenter human clinical trial that demonstrated IORT to be as effective as traditional radiation for certain women with early breast cancer.

IORT has the potential to replace as many as six and a half weeks of routine radiation therapy with 20-30 minutes of targeted radiation administered during surgery directly to the tumor site after lumpectomy.  

"IORT is a game-changer for women facing breast cancer – I like to call it one and done," said Dr. Alice Police, breast surgeon at Renaissance and co-founder of Pacific Breast Care in Newport Beach, Calif.  "For some women in the earlier stages of breast cancer, IORT makes it possible for them to have one surgery consisting of lumpectomy and single-dose radiation therapy and then go on with their life having completed their breast cancer treatment."

Unlike whole breast radiation treatment, which is administered five times per week for as many as six and a half weeks, IORT provides patients with a targeted single-dose radiation treatment delivered intraoperatively after removal of the tumor.  Radiation is applied for 20-30 minutes, exposing the affected tissue in the tumor bed from the inside.

"Dr. Police's passion for IORT as a revolutionary development in treating early breast cancers aligned with our mission to deliver the best surgical technologies available to patients in a comfortable and private outpatient environment," said Bruce Wallace, CEO and Administrator for Renaissance Surgical Arts at Newport Harbor.  "We looked at IORT device manufacturers and it was clear that the INTRABEAM System was the only responsible choice given its exclusive use in the TARGIT-A Clinical trial which provides 10 years of study and follow-up data to back its safety and efficacy."

The INTRABEAM System was the only radiotherapy device used in the TARGIT-A clinical trial, the largest randomized clinical trial conducted in the field of IORT for the treatment of breast cancer. The TARGIT-A trial was launched in 2000 and it enrolled 2,232 human patients throughout 28 centers in nine countries.  With up to 10-years of follow-up data, the study results demonstrate the equivalency of single-dose targeted IORT in comparison to external beam radiation therapy (EBRT) based on local recurrence.

Renaissance is one of only two outpatient surgery centers in the entire country to offer IORT using the INTRABEAM System, and is the only outpatient facility in the Western United States.  It is also the only location at all offering treatment in Orange, Riverside and San Diego counties using the clinically proven INTRABEAM System technology.  

"After learning about IORT from Dr. Police, I did my own research on the options, risks and benefits of whole breast and partial breast radiation in comparison to IORT," said Gila Jones, 58, of San Juan Capistrano, Calif.  "After feeling confident about effectiveness based on the TARGIT-A outcomes and considering my own lifestyle and other health concerns, IORT became the obvious choice for me.  Dr. Police did my surgery at Renaissance where I was treated as an honored guest."

Patients need to be evaluated by a specialist to determine if they are a good candidate for IORT.  To find out if you or someone you know is an IORT candidate, contact Renaissance Surgical Arts at Newport Harbor at 949-629-1400.  For more information about the TARGIT-A clinical trial, please visit www.targit-research.org or www.targit.org.uk.  For more information about the INTRABEAM® system, please visit www.meditec.zeiss.com/intrabeam.  

Renaissance Surgical Arts at Newport Harbor

Renaissance Surgical Arts at Newport Harbor is a professionally managed, but majority physician-owned facility in Orange County, Calif.  With eight ORs and two procedure rooms, the 20,000-plus square foot outpatient facility demonstrates how to mere cutting edge technology into a patient-centric environment that is as beautiful as it is functional.  The multispecialty outpatient center supports the area's best physicians representing a wide variety of specialties, including Cardiology, Ear Nose and Throat, Gastroenterology, Neurosurgery, Orthopedics, Spinal, Ophthalmology, Plastic and Reconstructive Surgery, Podiatry, Oncology, Interventional Radiology, GYN and General Surgery. Learn more at www.mysurgerycenter.net.

  • Logo 72dpi: Send2PressNewswire.com/image/11-0210-renarts_72dpi.jpg

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Renaissance Surgical Arts at Newport Harbor
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
2. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
3. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
4. New Non-Surgical Stem-Cell Procedure to Relieve Chronic Tendon Problems
5. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
6. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
7. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
8. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
9. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
10. Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination
11. New Minimally Invasive Surgical Procedure Restores Quality of Life in Patients With Potentially Debilitating Spinal Condition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... release financial results for the first quarter 2017 after ... The Company,s management team will host a corresponding conference ... ET. Investors interested in listening to the ... for domestic callers or (703) 326-3030 for international callers, ...
(Date:4/19/2017)... YORK , April 19, 2017 ... This report on the prostate cancer therapeutics ... the global market. Increasing prevalence of prostate cancer, ... innovation in the development of new drugs & ... prostate cancer drug due to lesser side effects ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 28, 2017 , ... The Texas Cord Blood Bank (TCBB), a program of ... team at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in collecting ... decide to donate. , “Women’s Hospital at Renaissance has been a collection partner ...
(Date:4/28/2017)... ... 28, 2017 , ... Bill Howe started his sewer and drain company in ... Howe joined the team, the Bill Howe brand was born and they began cultivating ... giving back to the San Diego community in which they worked, lived and were ...
(Date:4/28/2017)... ... 2017 , ... Intellitec Solutions announced the publication of a ... Dynamics GP solution that integrates to their PointClickCare EHR software package. With the ... Brooke Grove now has the capability to achieve its goal for a comprehensive ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... anniversary. SearchLight is the premier online modeling resource for fluorescence microscopists and optical ... active users during last 5 years spanning the globe, SearchLight has become a ...
(Date:4/27/2017)... ... , ... Healthcare companies are trying to meet talent shortages and find new ... resume. , “If you’re a healthcare executive open to new opportunities this year you’re ... ready as you are for a new job search. I’ve heard from countless job ...
Breaking Medicine News(10 mins):